DS2是一种新型的、具有选择性的δ-GABAA受体正变构调节剂。
Cas No.:374084-31-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
DS2 is a novel and selective positive allosteric modulator of δ-subunit-containing GABAA receptors. DS2 enhances the function of extrasynaptic δ-GABAA receptors by increasing the maximal response to GABA, while acting via an unknown site to provide receptor subunit selectivity[1-2]. DS2 is used to study the function of extrasynaptic δ-GABAA receptors and their role in stroke recovery[3-4].
In vitro, HEK293 cells stably expressing the human δ subunit were co-incubated with DS2 (1–5μM) and GABA (EC₂₅–₃₅) to measure the current response. DS2 selectively potentiated the current response or fluorescence signal at δ-GABAA receptors (α₄β₁δ and α₄β₃δ)[5]. Mouse thalamic ventrobasal (VB) neurons and cerebellar granule cells (CGCs) were pretreated with DS2 (3–10µM) for 30 seconds before recording in the presence of ambient GABA. DS2 significantly enhanced the tonic inhibitory current mediated by δ-subunit-containing δ-GABAA receptors[6].
In vivo, in the AppNL-F KI AD mouse model aged 12-16 months, DS2 (1-4mg/kg) was administered via intraperitoneal injection once daily for 5 consecutive days. DS2 significantly reduced anxiety-like behaviors and normalized the expression of δ-GABAA receptors[7]. In male C57BL/6J mice after stroke, DS2 (0.1-4mg/kg) was administered via intraperitoneal injection twice, at 1 hour and 24 hours post-stroke. DS2 significantly reduced infarct volume, improved motor function in the grid-walking and cylinder tasks, and lowered the levels of circulating pro-inflammatory cytokines (TNF-α, IL-6, IL-17)[8].
References:
[1] Lee HJ, Absalom NL, Hanrahan JR, et al. A pharmacological characterization of GABA, THIP and DS2 at binary α4β3 and β3δ receptors: GABA activates β3δ receptors via the β3(+)δ(-) interface. Brain Res. 2016 Aug 1;1644:222-30.
[2] Jensen ML, Wafford KA, Brown AR, et al. A study of subunit selectivity, mechanism and site of action of the delta selective compound 2 (DS2) at human recombinant and rodent native GABA(A) receptors. Br J Pharmacol. 2013 Mar;168(5):1118-32.
[3] Jensen NN, Wilhelmsen KS, Jensen MH, et al. Exploring the DS2 Scaffold for GABAA Receptor Modulation: Progress toward the Development of a GABAA δ-Subunit Preferring Negative Allosteric Modulator. J Med Chem. 2026 Feb 26;69(4):3811-3832.
[4] Rostrup F, Falk-Petersen CB, Harpso E K, et al. Structural Determinants for the Mode of Action of Imidazopyridine DS2 at δ-Containing γ-Aminobutyric Acid Type A Receptors. J Med Chem. 2021 Apr 22;64(8):4730-4743.
[5] Falk-Petersen CB, Søgaard R, Madsen KL, et al. Development of a Robust Mammalian Cell-based Assay for Studying Recombinant α4 β1/3 δ GABAA Receptor Subtypes. Basic Clin Pharmacol Toxicol. 2017 Aug;121(2):119-129.
[6] Wafford KA, van Niel MB, Ma QP, et al. Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus. Neuropharmacology. 2009 Jan;56(1):182-9.
[7] Zhang W, Liu T, Li J, et al. Decreased extrasynaptic δ-GABAA receptors in PNN-associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer's disease. Br J Pharmacol. 2024 Oct;181(20):3944-3975.
[8] Neumann S, Boothman-Burrell L, Gowing EK, et al. The Delta-Subunit Selective GABA A Receptor Modulator, DS2, Improves Stroke Recovery via an Anti-inflammatory Mechanism. Front Neurosci. 2019 Oct 29;13:1133.
DS2是一种新型的、具有选择性的δ-GABAA受体正变构调节剂。DS2通过增强GABA的最大反应来增强突触外δ-GABAA受体的功能，同时通过未知位点发挥作用以提供受体亚型选择性[1-2]。DS2可用于研究突触外δ-GABAA受体功能和中风恢复的相关研究[3-4]。
在体外，DS2（1–5μM）和GABA（EC₂₅–₃₅）同时孵育稳定表达人δ亚基的HEK293细胞时，检测细胞的电流反应。DS2能选择性地增强δ-GABAA受体（α₄β₁δ和α₄β₃δ）的电流反应或荧光信号[5]。DS2（3–10µM）预处理小鼠丘脑腹基底核（VB）神经元及小脑颗粒细胞（CGCs）30秒，随后在环境GABA存在下进行记录。DS2显著增强由δ-GABAA受体介导的紧张性（tonic）抑制电流[6]。
在体内，DS2（1-4mg/kg）每天一次腹腔注射，连续5天，用于处理12-16月龄的AppNL-F KI AD小鼠模型。DS2显著减少了小鼠的焦虑行为，并正常化了δ-GABAA受体的表达[7]。DS2（0.1-4mg/kg）于中风后1小时及24小时腹腔注射两次，用于中风C57BL/6J雄性小鼠。DS2显著减小了梗死体积，改善了网格行走和圆筒任务中的运动功能，并降低了循环促炎细胞因子（TNF-α，IL-6，IL-17）的水平[8]。
| Cell experiment [1]: | |
Cell lines | HEK293 Flp-In™ cells stably expressing the human GABAA receptor δ-subunit (HEK-δ), co-transfected with human α4 and β1/3 subunits |
Preparation Method | HEK-δ cells were cultured in DMEM with GlutaMAX-I supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C, 5% CO₂. For transient expression, cells were co-transfected with plasmids encoding α4 and β1/3 subunits. 2µM and 5µM DS2 were applied with a low concentration of GABA (1µM, GABA EC₂₅–₃₀). |
Reaction Conditions | 2µM and 5µM; immediate measurement. |
Applications | DS2 selectively potentiated the GABA-induced signal at α4β1δ and α4β3δ receptors but had no effect on binary α4β1/3 receptors. In patch clamp electrophysiology, DS2 potentiated the current response to 1µM GABA at α4β1δ receptors. DS2 is characterized as a δ-subunit selective positive allosteric modulator. |
| Animal experiment [2]: | |
Animal models | Adult (2-3 month old) and aged (22 month old) male C57BL/6J mice with a photothrombotically induced focal stroke in the motor cortex |
Preparation Method | For neuroprotection studies, mice received intraperitoneal (i.p.) injections of DS2 (0.1-4mg/kg) or vehicle 1 hour and 24 hours after stroke induction. For recovery studies, treatment with DS2 via subcutaneously implanted osmotic mini-pumps began 3 days post-stroke and continued for 28 days. |
Dosage form | 0.1-4mg/kg; i.p.; two injections (at 1h and 24h post-stroke). |
Applications | DS2 significantly reduced brain infarct volume and improved motor function recovery in grid-walking and cylinder tasks assessed 7 days post-stroke. DS2 also significantly decreased circulating levels of the pro-inflammatory cytokines TNF-α, IL-6, and IL-17 at 3 days post-stroke. When administered with a 3-day delay, DS2 improved recovery in the grid-walking task but not in the cylinder task. The effects were dose-dependent, with higher doses (1 and 4mg/kg) being less effective. |
References: | |
| Cas No. | 374084-31-8 | SDF | |
| 化学名 | 4-chloro-N-(2-(thiophen-2-yl)imidazo[1,2-a]pyridin-3-yl)benzamide | ||
| Canonical SMILES | ClC1=CC=C(C=C1)C(NC2=C(C3=CC=CS3)N=C4N2C=CC=C4)=O | ||
| 分子式 | C18H12ClN3OS | 分子量 | 353.83 |
| 溶解度 | <17.69mg/ml in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8262 mL | 14.1311 mL | 28.2622 mL |
| 5 mM | 565.2 μL | 2.8262 mL | 5.6524 mL |
| 10 mM | 282.6 μL | 1.4131 mL | 2.8262 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet